Marksans Pharma’s UK subsidiary Relonchem has received MHRA authorisation to market 250 mg and 500 mg Mefenamic Acid tablets.
Marksans Pharma’s UK subsidiary Relonchem has received MHRA authorisation to market 250 mg and 500 mg Mefenamic Acid tablets.